Contribution of the Human Gut Microbiome to the Development and Severity of Guillain-Barre Syndrome

Abstract

Campylobacter jejuni is a prolific gastrointestinal pathogen, accounting for a significant proportion of bacterial diarrheal disease and dysentery worldwide, and particularly afflicts military travelers leading to substantial duty days lost as well as a myriad of chronic health consequences. It is also estimated that C. jejuni infection in 1 of 1000 cases subsequently results in neurological sequelae and paralysis, referred to as Guillain-Barr Syndrome (GBS). Development of GBS is due to an aberrant autoimmune response directed against GM1ganglioside structures located on host nerve cells. A significant proportion of GBS cases are attributed to antecedent infection by C. jejunidue to its well-established mimicry of ganglioside structures by cell surface lipo oligosaccharides (LOS). Our preliminary research has identified other bacteria in the chicken gut microbiota that also mimic GM1-gangliosides. These organisms may play an important role in GBS development, causing immune-mediated tolerance or training toward the ganglioside antigen. Studies are required to establish the prevalence of these bacteria in the human gut and whether gut microbial signatures exist that are associated with GBS development. This project aims to determine the contribution of the human gut microbiota and carbohydrate-mediated immune responses to the development and severity of GBS. To determine the epidemiology and clinical outcomes of Guillain-Barr Syndrome (GBS)and its relationships with gastroenteritis in the military population.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2023
Accession Number
AD1217467

Entities

People

  • David R. Tribble

Organizations

  • Uniformed Services University of the Health Sciences

Tags

Fields of Study

  • Biology

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Immunology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech